United StatesPricing around “Gene editing approval path” is moving fast
Volumes on Gene editing equities are running above their 30-day average as “Gene editing approval path” approaches.
Event on Nov 11 · in 10 days
The prediction, in plain language
Too close to callIt is a coin flip, two scenarios, equally credible: the milestone is reached, or the milestone slips further out.
Prices imply 47% for this outcome, strengthening by 2 points in 24h, with medium confidence.
What to anticipate: Peer-reviewed publication. A surprise there can flip this reading within hours.
This is what market prices currently imply, not a certainty. Readings change as new information arrives.
+2 / 24h
Confidence: Medium
Sign in to follow this signal and set alerts.
Sign inWhy this signal
Data, Gene editing equities strengthened by 5 points over 24 hours, cross-checked against 2 linked markets.
Context, Research funding, patents and specialist suppliers are where science becomes measurable.
Interpretation, Taken together, prices point to an implied probability of 45% and a signal strength of 66/100 on this event.
Uncertainty, Confidence is medium. This is what prices imply today, not a forecast, one surprise can reverse it.
Cross-market confirmation
Gene editing equities
+5
Biotech index
in line
What could change it
- Peer-reviewed publication
- Public funding decision
Follow the story
Loading the latest headlines…
